Spectrum expands manufacturing capacity for production of Fusilev for injection

Spectrum Pharmaceuticals announced the U.S. Food & Drug Administration has approved an additional manufacturing facility for the production of Fusilev for injection. Spectrum has continued to increase the number of qualified third-party manufacturing sites approved for Fusilev production since this product was approved in 2011 for use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer. As recently reported, accounts ordering Fusilev increased by 13% from the second to third quarter; Fusilev market penetration has reached approximately 31%.